Gene therapy for rheumatoid arthritis. Theoretical considerations

Current understanding of the pathogenesis of rheumatoid arthritis has provided evidence that therapeutic benefit can be achieved by using antagonists targeted to the inflammatory cytokines involved, mainly tumour necrosis factor-α and interleukin-1. Gene delivery of antagonists, which can inhibit th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chernajovsky, Y., Annenkov, A., Herman, C., Triantaphyllopoulos, K., Gould, D., Dreja, H., Moyes, S.P., Croxford, J.L., Mageed, R.A., Podhajcer, O.L., Baker, D.
Formato: JOUR
Materias:
antirheumatic agent
antisense oligonucleotide
cytokine
cytokine receptor
immunoglobulin enhancer binding protein
immunoglobulin fragment
interleukin 1
interleukin 1 receptor blocking agent
interleukin 10
plasmid DNA
transforming growth factor beta1
tumor necrosis factor alpha
tumor necrosis factor alpha antibody
virus vector
cell type
clinical trial
complement system
gene targeting
gene therapy
human
major clinical study
mediator
meta analysis
priority journal
review
rheumatoid arthritis
Arthritis, Rheumatoid
Gene Therapy
Genetic Vectors
Humans
Acceso en línea:http://hdl.handle.net/20.500.12110/paper_1170229X_v12_n1_p29_Chernajovsky
Aporte de:
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires

Ejemplares similares

Ejemplares similares